Background: Arterial hypertension is associated with autonomic nervous system dysfunction. Different interventional strategies have been implemented in recent years for the reduction of sympathetic activity in patients with hypertension. However, the therapeutic benefit of increasing vagal tone in hypertensive patients remains largely unexplored.
INTRODUCTION
A rterial hypertension (AH) increases the risk of death from cardiovascular disease in adults aged between 40 and 69 years [1] . AH is believed to affect one in four people and accounts for approximately one billion cases worldwide [2] . Increased arterial blood pressure (BP) is one of the most crucial cardiovascular risk factors and has a dominant role in the pathogenesis of ischemic heart disease, heart failure, stroke, kidney failure and overall cardiovascular death. Despite important advances in the diagnosis and treatment of AH, a significant proportion of patients have insufficient disease management due to either resistance to current drug therapy [3] or poor drug compliance. Thus, there is a significant unmet clinical need to find alternative strategies to conventional pharmacotherapy.
Over the last three decades, a growing body of evidence has unequivocally shown that both the development and maintenance of AH are intimately linked to autonomic dysfunction, characterized by increased sympathetic activity [4, 5] and reduced cardio-vagal tone [6] . The great majority of preclinical and clinical studies have mainly focused on the detrimental effects of sustained sympathetic nervous system (SNS) overactivity on arterial BP control [7] [8] [9] [10] [11] [12] . This has generated considerable interest in novel autonomic modulation approaches such as renal nerve ablation [13] , deep brain stimulation [14] and carotid sinus stimulation [15] which have been shown to lower SNS activity, reduce arterial BP levels and prevent end-organ damage, particularly in treatment-resistant patients. In contrast, despite considerable evidence showing the beneficial effects of vagal nerve modulation on cardiovascular function [16] , little is known about the pathophysiological role of impaired vagal function in AH and thus, the effectiveness of activating parasympathetic efferent pathways for the treatment of hypertension remains largely unexplored. Here, we employed a pharmacogenetic approach to investigate the physiological consequences of long-term activation of vagal preganglionic neurons in the spontaneously hypertensive rat model.
METHODS

Animals
All animal experimentations were carried out in accordance with guidelines approved by University of São Paulo Institutional Animal Care and Use Committee (CEUA: 118/109-2). Experiments were performed on male adult hypertensive spontaneously hypertensive rats (SHRs) (8 weeks of age) and age-matched normotensive Wistar rats.
Viral vectors
Vagal preganglionic neurons of the dorsal vagal motor nucleus of the vagus nerve (DVMN), which express the transcriptional factor Phox2, were transduced using an artificial Phox2-activated promoter-PRSx8 as described previously [17] [18] [19] [20] . The DVMN neurons were targeted to express an artificial G protein-coupled receptor termed designer receptors exclusively activated by designer drugs (DREADD). These are mutated muscarinic receptors, which are selectively activated by an otherwise biologically inert ligand clozapine-n-oxide (CNO) [21] . A Gs-coupled version of this system (DREADD-Gs) fused with enhanced green fluorescent protein (eGFP) was used to activate neurons in a similar manner to that following activation of other Gscoupled receptors. A lentiviral vector was used to induce the expression of DREADD-Gs in DVMN neurons under the control of the artificial PRSX8 promoter (PRSx8-DREADDGs-eGFP-lentiviral vector). For control experiments, DVMN neurons were transduced to express eGFP (PRSx8-eGFPlentiviral vector). Vectors were generated in our laboratory facilities as described previously [22] using a DREADDs construct [23] . Lentiviral vector titers were approximately between 1 Â 10 12 transducing units/ml. Validation of efficacy of CNO-induced activation of Gs signaling in cells expressing DREADD-Gs was described in detail previously [22] .
In-vivo gene transfer
Rats were anesthetized [ketamine (80 mg/kg; ip) and xylasine (7 mg/kg, ip)] and placed in a stereotaxic frame (model 900; David Kopf Instruments, Tujunga, California, USA). Adequate level of anesthesia was confirmed by the absence of a withdrawal response to a paw pinch. SHRs and Wistar rats were injected in the DVMN with two microinjections per side (0.25 ml each, 0.05 ml/min) of a viral suspension containing PRSx8-DREADD-Gs-eGFP-lentiviral vector (DREADD-Gs; n ¼ 8 and n ¼ 4, respectively) or PRSx8-eGFP-lentiviral vector (e-GFP, n ¼ 7 and n ¼ 5, respectively) using the following coordinates from calamus scriptorius 0.5 mm rostral, 0.6 mm lateral, 0.8 mm ventral and 1.0 mm rostral, 0.8 mm lateral, 0.6 mm ventral. Anesthesia was reversed with atipamezole (1 mg/kg). All animals recovered normally without complications, received daily injections of buprenorphine for postoperative analgesic control (0.05 mg/kg subcutaneously for 5 days) and gained weight as expected for their age and size.
Application of clozapine-n-oxide
Systemic administration of CNO allowed us to activate Gs signaling in DVMN neurons expressing DREADD-Gs. The dose of CNO (0.3 mg/kg in 0.1 ml, subcutaneously) was based on the lowest concentration used in a previous study that was found to elicit robust activation of targeted neuronal populations and behavioral changes in conscious animals [24, 25] . Animals were allowed to recover from viral gene transfer surgery for 8 days before the start of CNO treatment. CNO injections were delivered daily by the same experimenter and at the same time every day for 21 consecutive days.
Arterial blood pressure measurements
After 19 days of CNO treatment (i.e. at 11 weeks of age), rats were implanted with intra-arterial catheters. Animals were anesthetized with halothane (3% in O 2 ) and a polyethylene tube (PE-10 connected to PE-50; Clay Adams, Parsippany, New Jersey, USA) filled with sterile saline containing heparin (50 U/ml) and penicillin G (2000 U/ml) was inserted into the left femoral artery and its tip was placed in the abdominal aorta caudal to the renal arteries [26] . The opposite end was tunneled subcutaneously and exteriorized through the upper back and sealed with a plastic cap. All animals received an intramuscular injection of penicillin G (24 000 IU) and streptomycin (10 mg). Catheters were flushed the following day with the same solution containing heparin and penicillin. Arterial pressure recordings were performed 2 days after arterial catheterization. On the day of the experiments, the catheter was connected to a pressure transducer (MLT844; ADInstruments, Sydney, NSW, Australia) coupled to a preamplifier (Bridge Amp, ML221; ADInstruments) that was connected to a Powerlab computer data acquisition system (PowerLab 16/30, ML880; ADInstruments). Arterial pressure measurements were taken between 0800 and 1700 h by an experimenter that was blind to the animal condition. Data was acquired in conscious animals for 60 min during quiet resting periods.
Power spectral analysis
Spectral analysis of the systolic pressure variability was performed off-line to estimate the relative level of sympathetic and parasympathetic activity in rats at 11 weeks of age. Mean, systolic and diastolic arterial pressures (MAP, SAP and DAP; mmHg, respectively), pulse interval (ms) and heart rate (HR; bpm) were measured from the arterial pressure recording using LabChart 8.0 (model Powerlab 8SP; ADInstruments). Data was acquired after a 10-min period of stabilization. Only data sets containing stable measurements of SAP and pulse interval without artifacts or large sudden BP changes were selected for analysis. An algorithm was used to detect beat-to-beat inflection points in the pulsatile arterial pressure signal. SAP and pulse interval variability analysis was carried out in time and frequency domains using custom software CardioSeries V2.4 (http:// www.danielpenteado.com/) as described previously [27] . Briefly, SAP and pulse interval power spectral density were estimated by Fast Fourier Transform algorithm for time series. Using 10 Hz of interpolation rate, beat-by-beat series were divided in half overlapping sequential sets with 512 points. The spectra of SAP and pulse interval were integrated into a low-frequency band (low frequency: 0.2-0.75 Hz, indicating mainly sympathetic influences) and a high-frequency band (0.75-3 Hz, indicative mainly of cardio-vagal tone). The results were expressed in absolute (ms 2 ) and normalized units (nu) obtained by calculating the percentage of low-frequency and high-frequency power with regard to the total power of the spectrum minus the very low-frequency band (<0.2 Hz) [28] . Sympathovagal balance was also calculated by assessing the low-frequency/high-frequency ratio of pulse interval variability [27] [28] [29] [30] .
Spontaneous baroreflex sensitivity
A beat-by-beat time series of SAP and pulse interval was scanned in a 60-min data set acquired during quiet rest, searching for sequences of at least four consecutive beats in which arterial pressure increases were followed by pulse interval lengthening (up-sequence) and arterial pressure decreases were followed by pulse interval shortening (down-sequence) with a delay of 0, with no threshold in SAP and pulse intervals and a linear correlation of more than 0.8. The slope of the linear regression lines between SAP and pulse interval was taken as a measure of spontaneous baroreflex sensitivity (SBR). The baroreflex effectiveness index, which provides information on baroreflex function that is complementary to spontaneous SBR, was also calculated [31] . It was defined as the ratio between the number of SAP ramps followed by respective reflex changes in pulse interval and the total number of SAP ramps (independent of whether accompanied by the corresponding reflex pulse interval ramps) observed over the time window studied.
Immunohistochemistry procedures
At the end of the in-vivo experiments, the rats transduced to express DREADD-Gs or eGFP in the DVMN neurons were deeply anesthetized with sodium pentobarbital (60 mg/kg), injected with heparin (500 U, intracardially) and perfused through the ascending aorta with 0.9% saline solution followed by 4% phosphate-buffered (0.1 mol/l, pH 7.4) paraformaldehyde. After 12 h of postfixation and subsequent cryoprotection in 30% sucrose, 40-mm-thick coronal sections were collected along the rostro-caudal extent of the medulla oblongata. Sections were processed for the immunohistochemical detection of choline acetyl-transferase (ChAT). Tissue was incubated in goat anti-ChAT (1 : 500, Chemicon, raised against human placental ChAT) followed by donkey antigoat Alexa Fluor 594 (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA). The specificity of the antibodies has been validated previously [32, 33] .
Cell mapping, counting and imaging
A conventional multifunction microscope [brightfield, darkfield and epifluorescence; Zeiss Axioskop 2 microscope (Oberkochen, Germany)] was used for all observations except when indicated. ImageJ software (National Institutes of Health, Bethesda, Maryland, USA) was used to count the various types of neuronal profiles within a defined area.
A one-in-six series of 40-mm brain sections was used per rat, for a total distance of 240 mm of separation between slices. The sections were counted bilaterally, and the numbers reported correspond exactly to the counts obtained in one series of sections. Section alignment between brains was completed relative to a reference section. Briefly, to align sections around the nucleus of the solitary tract level, the section containing the mid-area postrema was identified in each brain and assigned the level 13.8 mm caudal to Bregma (Bregma ¼ À13.8 mm). Levels rostral or caudal to this reference section were determined by adding a distance corresponding to the interval between sections multiplied by the number of intervening sections.
Photographs were taken with a 12-bit color CCD camera (CoolSnap, Roper Scientific, Tuscon, Arizona, USA; resolution 1392 X 1042 pixels). The files were exported to the Canvas 9 software-drawing program (CAnvas 9 software, Fort Lauderdale, Florida, USA) for final modifications. The neuroanatomical nomenclature is based on Paxinos and Watson Atlas of Neuroanatomy [34] .
Data analysis
Data normality was assessed using the Shapiro-Wilk test, and all the normally distributed data were expressed as the mean AE SEM. The data regarding number of neurons (ChAT þ , ChAT þ /eGFP þ ) and cardiovascular variables (i.e. SAP, DAP, MAP, HR) were compared between groups and across time points using two-way analysis of variance, with repeated measures for only the time factor. When applicable, the Student Newman Keuls post hoc test was used. Sigma Stat version 3.0 package (Jandel Corporation, Point Richmond, California, USA) was used for all analysis. Significance level used was P less than 0.05.
RESULTS
Expression of designer receptors exclusively activated by designer drugs-enhanced green fluorescent protein in dorsal vagal motor nucleus neurons
The number and location of neurons expressing DREADD-Gs in the DVMN was mapped in each rat by identifying DREADDGs-eGFP fluorescence signal in vagal preganglionic neurons immunoreactive to ChAT (Fig. 1a-c) . On average, DREADDGs was detected in 220 AE 13 neurons counted in five coronal sections (n ¼ 7). Of the neurons expressing DREADD-Gs in all counted sections, 94 AE 5% had detectable ChAT-immunoreactivity. Thus, 70 AE 6% of ChAT-immunoreactive neurons in the DVMN were found to express the transgene (Fig. 1d) .
Effect of long-term activation of dorsal vagal motor nucleus neurons on arterial blood pressure Figure 2 shows arterial BP measurements obtained in SHRs and Wistar rats expressing DREADD-Gs or control eGFP after administration of CNO for 21 consecutive days. Arterial BP levels were significantly lower in SHRs transduced to express DREADD-Gs in the DVMN compared with SHRs expressing eGFP ( Fig. 2a and b) 
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Journal of Hypertension www.jhypertension.com[F (3, 31) (Fig. 2a-c) . HR was also found to be lower in SHRs expressing DREADD-Gs in the DVMN (302 AE 5 bpm) compared with SHRs expressing eGFP (370 AE 6 bpm, [F (3, 31) ¼ 68,08; P < 0.01]; Fig. 2d ). Resting SAP, DAP, MAP and HR were significantly higher in SHRs expressing DREADD-Gs compared with Wistar rats expressing either DREADD-Gs or eGFP (P ¼ 0.021) (Fig. 2a-d ). Cardiovascular parameters were not different between control Wistar rats expressing DREADD-Gs or eGFP in the DVMN (Fig. 2a-d) .
Repetitive activation of dorsal vagal motor nucleus neurons increases spontaneous baroreflex sensitivity Figure 3a and b show the spontaneous baroreflex sensitivity gain and baroreflex effectiveness index in SHRs and Wistar rats transduced to express DREADD-Gs or eGFP in the DVMN. The results showed that rats from both groups expressing DREADD-Gs in the DVMN had higher spontaneous baroreflex sensitivity (7.7 AE 0.7 in SHRs expressing DREADD-Gs, vs. 4.7 AE 0.6 in SHRs expressing eGFP, P ¼ 0.024 and 7.3 AE 0.5 in Wistars expressing DREADDGs vs. 5.1 AE 0.7 in Wistars expressing eGFP, P ¼ 0.03) and baroreflex effectiveness index (0.15 AE 0.025 in SHRs expressing DREADD-Gs vs. 0.073 AE 0.03 in SHRs expressing eGFP, P ¼ 0.035 and 0.13 AE 0.01 in Wistar expressing DREADD-Gs vs. 0.08 AE 0.02 in Wistar expressing eGFP, P ¼ 0.038) (Fig. 3a and b) .
Heart rate and systolic arterial pressure and variability
The results of SAP and HR (pulse interval) variability in the time and frequency domains are shown in Figs. 3c and d and 4a-d. SAP variance and SAP low frequency were found to be lower in SHRs expressing DREADD-Gs as compared with SHRs expressing eGFP (P ¼ 0.043) and no change was observed in Wistar rats ( Fig. 3c and d) . The analysis of SAP variability showed no differences in pulse interval variance in either group. However, the total power in both, the lowfrequency and the high-frequency components was significantly reduced in SHRs expressing DREADD-Gs compared with SHRs expressing eGFP (P ¼ 0.034) (Fig. 4b and c) . Moreover, sympathovagal balance assessed by the lowfrequency/high-frequency ratio, was shown to be lower in SHRs expressing DREADD-Gs compared with SHRs expressing eGFP (P ¼ 0.032, Fig. 4d ), thus suggesting a dominance of parasympathetic influences.
DISCUSSION
In this study, we have shown that using a pharmacogenetic approach for repetitive stimulation of DVMN neurons for 21 days produced significant cardiovascular benefits in SHRs, including decreased arterial BP and improved spontaneous baroreflex sensitivity. These data are consistent with previous studies showing improved cardiac and vascular function by either direct [electrical vagal stimulation, acetylcholine (ACh) administration and ACh receptor activation] or indirect vagal modulation (adenosine, cholinesterase inhibitors, statins and exercise training) (see [16] for review). In recent years, vagal modulation techniques such as baroreflex activation therapy and direct vagal nerve stimulation have been proposed as supplementary therapies for the treatment of AH [35] . However, to our best knowledge this is the first study where a well defined population of vagal preganglionic neurons has been selectively targeted for repetitive activation of central parasympathetic pathways in an animal model of AH.
Our results showed that arterial BP was significantly reduced in SHRs transduced to express DREADD-Gs in the DVMN compared with SHRs expressing control eGFP, whilst Wistar rats showed no changes in cardiovascular parameters. This suggests that DVMN efferents might play an important role in the control of arterial BP, however, the mechanisms are unclear. ACh decreases blood vessel resistance by inducing phosphorylation of the rate-limiting enzyme involved in the biosynthesis of nitric oxide (NO), endothelial NO synthase. NO reduces intracellular calcium availability, resulting in a decrease in myosin phosphorylation and vasorelaxation, which would enable an overall reduction in systemic arterial BP. However, skeletal muscle resistance arterioles are paradoxically devoid of cholinergic innervation and therefore, changes in total peripheral resistance are highly unlikely to underlie the arterial BP-lowering effect induced by direct stimulation of parasympathetic pathways from the DVMN. Another plausible mechanism that might help to explain our results
FIGURE 4
Power spectral analysis of the pulse interval variability and spontaneous baroreflex sensitivity after long-term activation of designer receptors exclusively activated by designer drugs-expressing neurons in the dorsal motor nucleus of the vagus in spontaneously hypertensive rat and Wistar rats. Summary data showing that long-term activation of dorsal vagal motor nucleus of the vagus nerve neurons expressing designer receptors exclusively activated by designer drugs within the dorsal vagal motor nucleus of the vagus nerve results in significant changes in (a) pulse interval variability; (b) low-frequency component of pulse interval (%); (c) high-frequency component of pulse interval (%) and (d) low-frequency/high-frequency ratio in spontaneously hypertensive rat and Wistar rats. Data are presented as mean AE SEM.
Ã P < 0.05, significant difference between spontaneously hypertensive rats or Wistar rats expressing enhanced green fluorescent protein and spontaneously hypertensive rats and Wistar rats expressing designer receptors exclusively activated by designer drugs in the dorsal vagal motor nucleus of the vagus nerve. N ¼ 4-8/group of rats.
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Journal of Hypertension www.jhypertension.commight involve the recruitment of vagal efferents that regulate cardiac contractility. Recent studies have shown that pharmacological activation of cardiac preganglionic vagal neurons that reside in the left caudal DVMN trigger profound reductions in left ventricular (LV) dp/dt max in the rat [19] . This suggests that regular stimulation of DVMN neurons may have induced repetitive and prolonged reductions in cardiac output (CO) at the expense of reduced stroke volume and LV inotropy which in the long term, may have contributed to lower arterial BP levels in SHRs. However, measurements of cardiac inotropy in animals before and after extended periods of repetitive stimulation of DVMN neurons are needed to validate these claims.
Selective silencing of DVMN neurons has been shown to lead to significant increases in dp/dt max , LV end SAP and MAP, suggesting that DVMN neurons provide a tonic inhibitory muscarinic influence on LV contractility [19] . Therefore, conditions that promote DVMN neuronal dysfunction, a selective loss of parasympathetic preganglionic neurons supplying the heart or a remodeling of their cardiac projections, might result in suppressed tonic inhibitory vagal influences on LV contractility which might contribute to the development of AH. Previous studies have shown that parasympathetic neuronal dysfunction is a common feature in animal models of cardiovascular disease such as heart failure and chronic intermittent hypoxia in which increased gamma-aminobutyric acid-ergic/glycinergic neurotransmission and decreased excitatory neurotransmission in the DVMN and nucleus ambiguous result in reduced neuronal excitability and lower parasympathetic tone [36, 37] . Similar mechanisms are likely to operate in the SHR and should be further investigated in future studies. Histological analysis of ChAT immunofluorescence revealed that SHRs and Wistar rats have similar neuronal densities in the DVMN. However, the number of DVMN neurons retrogradely labeled from the heart was previously found to be significantly reduced in adult SHRs compared with young SHRs and adult Wistar Kyoto rats [38] . This discrepancy suggests that the number of cardiovagal neurons that project to the heart is probably too small as to make a significant contribution to the overall population of vagal neurons residing in the DVMN and thus, a loss of cardiovagal neurons in adult SHRs may not have a major impact on the total number of DVMN neurons. Despite this, a small reduction of cardiovagal preganglionic neurons in the SHRs might be sufficient to lead to a loss of the inhibitory vagal tonic control of cardiac inotropy. Together, this evidence suggests that AH might be associated with impaired DVMN functionality in the SHR and thus, increasing neuronal activity with our pharmacogenetic approach might have helped to attenuate disease progression. The lack of arterial BP-lowering effect in Wistar rats expressing DREADD-Gs suggests that the dose of CNO was probably too small to produce biologically relevant increases in the level of activity in tonically active healthy neurons.
Stimulation of DVMN neurons was also associated with significant increases in baroreflex gain and effectiveness, both in SHRs as well as in Wistar rats. This suggests that DVMN stimulation might have improved baroreflex function, perhaps by inducing protective effects in baroreceptor function at the level of the great vessels. In recent years, several reports indicate that mechanical insults that increase arterial stiffening contribute directly to the development of AH. Arterial stiffness is caused by disruption of elastin integrity in the aortic wall in particular with ageing, diabetes and chronic kidney disease. Stiffening at the level of the aortic root, impairs the Windkessel mechanism at this important interface, thereby reducing wave reflection and leading to increased central pulsatile pressure and transmission of excessive pulsatile energy that is known to promote end-organ damage. More importantly, reduced arterial compliance at higher pressures is believed to hamper baroreceptor activation thus causing a dysfunction in baroreflex control of HR and peripheral resistance. Studies performed in mouse models of impaired elastin expression have shown that stiffening of the aorta precedes the development of hypertension and subsequent increments in systolic pressure were inversely proportional to elastin content in the aorta [39] . Significantly, bilateral vagotomy in rats has been shown to induce similar structural remodeling changes leading to increased stiffening of the aorta [40] . Even though arterial BP was not reported in this study, this evidence suggests that the vagus nerve may prevent age-related structural changes in the great vessels that may contribute to the development of AH. Future studies should endeavor to investigate whether long-term stimulation of DVMN efferent pathways induces protective metabolic and structural mechanisms that help to preserve and/or restore arterial wall compliance and thus facilitate arterial baroreceptor signaling.
Our data showed that long-term activation of vagal preganglionic neurons within the DVMN resulted in a reduction in HR and SBP variance exclusively in SHRs. A bradycardic effect in SHRs might contribute to lower CO and produce concomitant reductions in arterial BP in the SHRs expressing DREADD-Gs. This reduction of HR in SHRs might have been caused by accentuated antagonism of cardio-stimulatory sympathetic neurotransmission induced by ACh release at postganglionic nerve terminals [41] rather than by increased vagal influence on cardiac chronotopy since cardiac vagal preganglionic neurons that control the activity of the sino-atrial node are generally believed to be located in the ventrolateral aspect of the nucleus ambiguous [42, 43] whilst DVMN neurons that were targeted in this study have virtually no influence on the control of HR [42] . This is supported by pulse interval variability analysis, showing significant reductions in the low-frequency component, consistent with decreased sympathetic tone. This effect was more pronounced in SHRs than in Wistar rats because SHRs have augmented sympathetic nerve trafficking and therefore would be more sensitive to accentuated antagonism by ACh.
Our results are consistent with recent studies showing that pharmacological activation of parasympathetic signaling elicits beneficial effects in the circulatory system. Transdermal application of scopolamine has been shown to decrease arterial BP, increase baroreflex sensitivity and accentuate vagal-cardiac modulation of sinus node in patients with mild hypertension [44] , supporting the hypothesis that increasing cardiovascular parasympathetic activity might have beneficial effects in patients with AH. More recently, systemic administration of choline was shown to restore the impaired cardiac function in SHRs, as evidenced by decreases in HR, SBP, LV systolic pressure, dp/dt max and increases in ejection fraction and fractional shortening [45] . This effect was accompanied by restored baroreflex sensitivity in SHRs and profound anti-inflammatory effects, including downregulation of IL-6 and TNF-a and increased expression of IL-10 in the mesenteric arteries of SHRs, thus indicating that choline improved vagal activity [45] . Similarly, chronic increase of ACh availability induced by administration of antiacetylcholinesterase agents with central and/or peripheral action, attenuated the development of hypertension, increased cardiac vagal tone, improved arterial pressure and pulse interval variability and reduced plasma levels of TNF-a, IL-6 and IFN-g [46] . Together, these pharmacological studies suggest that ACh might attenuate the harmful cardiovascular effects of systemic low-grade inflammation, including endothelial dysfunction, oxidative stress and autonomic dysfunction. However, the effect of DVMN neuronal activation on the expression of proinflammatory mediators and signaling mechanisms requires further investigation. Control of low-grade signaling inflammation by stimulation of DVMN circuits may have a significant impact on the control of autonomic balance and cardiovascular homeostasis and ultimately contribute to the reduction in arterial BP levels in the SHR.
Our study has some limitations. We employed adult SHRs with fully-established AH and 21 days of DVMN stimulation with CNO was relatively short. Thus, it remains to be determined whether these effects are similar or perhaps more effective when animals receive the treatment at different stages (i.e. prehypertensive stage or further down in the presence of end-organ damage) and whether arterial BP-lowering effects can be sustained for considerably longer periods (months to years). From a technical point of view, one of the major technical limitations was that BP measurements were only acquired until the end of the study and for relatively short periods of time (normally 1 h). Thus, longer data acquisitions were not possible, especially at night, so we were not able to assess the time course of the BP-lowering effects of DVMN activation and whether BP dipping was restored in SHRs. Finally, we did not determine whether the amount of lentiviral particles delivered achieved a maximum infection rate which could have affected the magnitude of the arterial BP-lowering effect we obtained. However, despite these limitations, our study provides unequivocal evidence that shows that activation of DVMN neurons for 3 weeks is enough to substantially lower arterial BP levels in adult SHRs and improve autonomic dysfunction.
In conclusion, using a pharmacogenetic approach for highly selective recruitment of vagal efferent projections in the DVMN, we demonstrate that long-term activation of central parasympathetic pathways exerts arterial BP-lowering effects in SHRs. Our data suggest that cardiac preganglionic neurones in the DVMN are important targets for increasing parasympathetic activity to the heart and may provide a therapeutic strategy to help control AH and prevent its detrimental effects.
